Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DB7V3D
|
|||
| Drug Name |
BMS-984923
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1 | [1] | |
| Company |
Yale University, NIA
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04805983) An Open-Label, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923. U.S.National Institutes of Health. | |||
| REF 2 | Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes. Cell Rep. 2017 Jul 5;20(1):76-88. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.